Hospital
Midland County Hospital District
Midland County Hospital District was paid $15.23M by Medicaid between Jan 2018 and Dec 2024, across 123 billing codes. Its largest line is 99284, emergency room visit (serious) — 40% of everything it billed.
33Billing provider infoMIDLAND COUNTY HOSPITAL DISTRICT
MIDLAND, TX 79701
MIDLAND, TX 79701
33aNPI1255325817assigned 09/09/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$15.23M
24GClaims264,246
24DCodes billed123
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#7 of 109
Median peer was paid$1.15M
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15 | $3K | |
| 2019 | 194 | $8K | |
| 2020 | 6,400 | $267K | |
| 2021 | 66,376 | $3.33M | |
| 2022 | 73,225 | $4.63M | |
| 2023 | 80,574 | $5.13M | |
| 2024incomplete | 37,462 | $1.86M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 40% | 17,608 | 16,583 | $6.02M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 15% | 3,950 | 3,841 | $2.36M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 35,526 | 34,431 | $1.78M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 5.8% | 295 | 286 | $882K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.7% | 2,719 | 2,507 | $708K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 3.5% | 9,954 | 9,775 | $530K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.3% | 11,965 | 11,693 | $348K |
| 71045 | Radiologic examination, chest; single view | 1.9% | 8,273 | 7,868 | $286K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.7% | 13,356 | 12,914 | $261K |
| 80053 | Comprehensive metabolic panel | 1.6% | 20,011 | 18,334 | $238K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 4,537 | 4,477 | $234K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.2% | 309 | 305 | $187K |
111 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 21,204 | $175K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,518 | $137K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 140 | $87K |
| 87081 | <1% | 7,593 | $76K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 975 | $68K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 310 | $50K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,346 | $46K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 775 | $46K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 277 | $46K |
| 81001 | <1% | 10,977 | $40K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,276 | $40K |
| 87428 | <1% | 579 | $37K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,678 | $34K |
| 36415 | Collection of venous blood by venipuncture | <1% | 26,965 | $32K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,588 | $31K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 520 | $27K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,596 | $26K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 257 | $22K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 60 | $22K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,177 | $19K |
| G0378 | Hospital observation service, per hour | <1% | 287 | $18K |
| 83690 | <1% | 2,742 | $17K | |
| 99188 | <1% | 28 | $17K | |
| 84484 | <1% | 2,182 | $16K | |
| 84703 | <1% | 1,760 | $15K | |
| 86850 | <1% | 971 | $14K | |
| 80061 | Lipid panel | <1% | 862 | $14K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 261 | $11K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,156 | $11K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 252 | $10K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 922 | $10K |
| 84439 | <1% | 786 | $10K | |
| 84702 | <1% | 744 | $9K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 240 | $9K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 240 | $8K |
| 76801 | <1% | 87 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 454 | $8K |
| 82728 | <1% | 285 | $7K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 42 | $7K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 12 | $7K |
| 84145 | <1% | 242 | $6K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 50 | $5K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 120 | $5K |
| 87077 | <1% | 1,099 | $5K | |
| 81025 | <1% | 432 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,406 | $4K |
| 83735 | <1% | 1,101 | $4K | |
| 83880 | <1% | 452 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,453 | $4K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 28 | $4K |
| 87186 | <1% | 860 | $4K | |
| 83540 | <1% | 289 | $3K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 16 | $3K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 125 | $3K |
| 81003 | <1% | 1,197 | $3K | |
| 83550 | <1% | 173 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 83 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,398 | $2K |
| 86900 | <1% | 967 | $2K | |
| 83605 | <1% | 617 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,055 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,769 | $2K |
| 84030 | <1% | 216 | $2K | |
| 85730 | <1% | 949 | $2K | |
| 86901 | <1% | 960 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 13 | $2K |
| 84466 | <1% | 79 | $2K | |
| 85610 | <1% | 1,112 | $1K | |
| 74018 | <1% | 27 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 28 | $1K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 396 | $1K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 235 | $1K |
| 85018 | <1% | 479 | $1K | |
| 85014 | <1% | 479 | $1K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 55 | $1K |
| 82962 | <1% | 1,467 | $965.24 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 88 | $864.53 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 571 | $856.30 |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 131 | $851.11 |
| 87040 | <1% | 133 | $776.66 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 65 | $708.26 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 235 | $673.27 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 56 | $521.31 |
| 36416 | <1% | 384 | $448.13 | |
| 82607 | <1% | 14 | $446.12 | |
| 85027 | <1% | 87 | $357.76 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 286 | $341.37 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 276 | $334.75 |
| 83655 | <1% | 31 | $323.94 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 542 | $280.24 |
| 82247 | <1% | 30 | $251.03 | |
| 0352U | <1% | 101 | $210.66 | |
| 87210 | <1% | 43 | $205.29 | |
| A4565 | Slings | <1% | 12 | $164.45 |
| 0353U | <1% | 111 | $155.35 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 25 | $134.29 |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 20 | $132.48 |
| 85379 | <1% | 14 | $87.96 | |
| 96376 | <1% | 15 | $78.84 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 30 | $75.53 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 349 | $61.24 |
| 85652 | <1% | 12 | $52.64 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 56 | $43.04 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 17 | $35.14 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 13 | $32.47 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 222 | $18.56 |
| 87205 | <1% | 13 | $11.04 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 166 | $9.48 |
| 82565 | <1% | 12 | $4.30 | |
| A6223 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size more than 16 sq. in., but less than or equal to 48 sq. in., without adhesive border, each dressing | 0% | 12 | $0.00 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMEYERS, PAUL (CEO)